{"entity":{"id":"hp518","kind":"drug","name":"HP518","aka":[],"tldr":"HP518 is an experimental oral PROTAC protein degrader from Hinova Pharmaceuticals, in phase 2 trials for metastatic castration-resistant prostate cancer.","summary":"HP518 is an oral PROTAC protein degrader from Hinova Pharmaceuticals. An oral degrader that removes both the normal androgen receptor and receptor variants resistant to enzalutamide. Its furthest stage is phase 2, for metastatic castration-resistant prostate cancer. ClinicalTrials.gov registers it in 2 studies linked below. Hinova: 'At present HP518 is in Phase I/II clinical study'. NCT06155084 phase 1/2 recruiting; Australian phase 1 NCT05252364 completed. Whether it works in people has not been established unless a trial below reports it.","status":"phase-2","asOf":"2026-11-03","links":[{"label":"Hinova Pharmaceuticals: hinovapharma.com","url":"https://www.hinovapharma.com/en/chanpinxianguan.html"},{"label":"Hinova Pharmaceuticals: hinovapharma.com","url":"https://www.hinovapharma.com/en/chanpinxianguan.html"},{"label":"ClinicalTrials.gov: trials of HP518","url":"https://clinicaltrials.gov/search?intr=HP518"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["prostate-mcrpc"],"sections":[],"technologies":[],"targets":["androgen-receptor"],"drugs":[],"companies":["hinova-pharmaceuticals"],"institutions":[],"pathways":[],"terms":[],"trials":["nct06155084","nct05252364"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"provenance":{"editedBy":"OnCo gap audit, class 5 (company pipeline pages and ClinicalTrials.gov v2)","editedOn":"2026-11-03"},"code":"HP518","modality":"Oral PROTAC protein degrader","mechanism":"An oral degrader that removes both the normal androgen receptor and receptor variants resistant to enzalutamide.","approvals":[],"mechanismSteps":[],"toxicity":[],"access":[],"regulatoryEvents":[]},"route":"/drugs/hp518/","neighbours":{"cancer":[{"id":"prostate-mcrpc","kind":"cancer","name":"Metastatic castration-resistant prostate cancer","route":"/cancers/prostate-mcrpc/"}],"target":[{"id":"androgen-receptor","kind":"target","name":"Androgen receptor","route":"/targets/androgen-receptor/"}],"company":[{"id":"hinova-pharmaceuticals","kind":"company","name":"Hinova Pharmaceuticals","route":"/companies/hinova-pharmaceuticals/"}],"trial":[{"id":"nct06155084","kind":"trial","name":"A Study to Assess the Safety, Pharmacokinetics, and Anti-Tumor Activity of Oral HP518 in mCRPC Patients","route":"/trials/nct06155084/"},{"id":"nct05252364","kind":"trial","name":"A Study to Assess the Safety, Pharmacokinetics, and Anti-Tumor Activity of Oral HP518 in Patients With Metastatic Castration-Resistant Prostate Cancer","route":"/trials/nct05252364/"}]}}